OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

S Travis; T Hisamatsu; M Fischer; M Dubinsky; V Jairath; M Chen; M Ferrante; L Peyrin-Biroulet; B Siegmund; T Hunter Gibble; Z Lin; M Protic; N Morris; S Ghosh

Journal ArticleOPEN ACCESS

OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

Travis S
Hisamatsu T
Fischer M
et al.

Journal of Crohn's and Colitis (2024) 18(Supplement_1) i21-i23

DOI: 10.1093/ecco-jcc/jjad212.0012

N/ACitations

8Readers

Abstract

Background: Mirikizumab (miri), an anti-IL-23p19 antibody, is approved for the treatment of ulcerative colitis and under development for Crohn's disease (CD). We investigated how miri impacted fatigue, bowel urgency, and health-related quality of life (HRQoL) through 52 weeks in patients with moderately to severely active CD in the Phase 3 VIVID-1 study.

Cite

CITATION STYLE

APA

Travis, S., Hisamatsu, T., Fischer, M., Dubinsky, M., Jairath, V., Chen, M., … Ghosh, S. (2024). OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial. Journal of Crohn’s and Colitis, 18(Supplement_1), i21–i23. https://doi.org/10.1093/ecco-jcc/jjad212.0012

OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

Abstract

Cite

Register to see more suggestions